Recently, Kexing Biopharm's overseas product, Paclitaxel for Injection (Albumin-Bound), received marketing authorization from the Swiss Agency for Therapeutic Products (Swissmedic).

Recently, Kexing Biopharm and Shandong Xinhua Pharmaceutical Co., Ltd. ("Xinhua Pharmaceutical", 000756.SZ) further strengthened their partnership by reaching a cooperation agreement to commercialize Icosapent Ethyl Soft Capsules in Saudi Arabia and the United Arab Emirates (UAE).

Recently, the bevacizumab biosimilar introduced by Kexing Biopharm (688136.SH) and developed by BioDlink was approved for marketing by Mexico’s regulatory authority, COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios).

Recently, the Head of Global Business Development at Kexing Biopharm Co., Ltd. (hereinafter referred to as "Kexing Biopharm", 688136.SH) was invited to attend the 2026 BFC-Cytiva Global Healthcare Summer BD & Investment Conference.

Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly owned subsidiary of Kexing Biopharm, successfully completed the first participant enrollment and dosing in the Phase I clinical study of GB19 Injection

Reminton® (Infliximab for Injection), introduced by Kexing Biopharm from Mabpharm, has recently received approval from the National Medical Products Administration (NMPA) for a new indication.

From June 16 to 18, the CPHI & PMEC China 2026 was held at the Shanghai New International Expo Center.

Recently, Kexing Biopharm (688136.SH) and Sinotherapeutics (688247.SH) signed an exclusive commercialization licensing agreement for Tofacitinib Citrate Sustained-Release Tablets in the Kuwait and Mexico markets, jointly advancing the product’s expansion into international markets.